BEFORE & AFTER
See results of patients treated with KYBELLA® injection. Individual results may vary.
This site is intended for US healthcare professionals.
See our new privacy terms at https://privacy.abbvie/.
ABOUT TREATMENT
What to know about KYBELLA® dosing and administration:
- KYBELLA® is injected into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm2
— A single treatment consists up to a maximum of 50 injections, 0.2 mL each (up to a total of 10 mL), spaced 1 cm apart1
— Up to 6 single treatments may be administered at intervals no less than 1 month apart1 - In clinical studies, many KYBELLA® subjects experienced visible results in 2 to 4 treatment sessions (see tables below)2
— 59% of subjects received 6 KYBELLA® treatments in clinical trials1
Pivotal clinical trials2
≥ 1-Grade Improvement
| Treatment Time Points | KYBELLA® | Placebo |
|---|---|---|
| Eval Tx 1a | 8% | 2% |
| Eval Tx 2a | 28% | 7% |
| Eval Tx 3a | 43% | 12% |
| Eval Tx 4a | 55% | 14% |
| Eval Tx 5a | 66% | 15% |
| 4 Weeksb | 72% | 22% |
| 12 Weeksb | 72% | 21% |
| 24 Weeksb | 74% | 20% |
≥2-Grade Improvement
| Treatment Time Points | KYBELLA® | Placebo |
|---|---|---|
| Eval Tx 1a | 0% | 0% |
| Eval Tx 2a | 0% | 0% |
| Eval Tx 3a | 1% | 0% |
| Eval Tx 4a | 4% | 1% |
| Eval Tx 5a | 4% | 0% |
| 4 Weeksb | 15% | 2% |
| 12 Weeksb | 17% | 2% |
| 24 Weeksb | 20% | 1% |
- In clinical trials, subjects were administered an average of 6.4 mL at the first treatment session, and subjects who received all 6 treatments were administered an average of 4.4 mL at the sixth treatment session; no more than 10 mL per treatment session may be administered1
- The safe and effective use of KYBELLA® depends on the use of the correct number of and locations for injections, proper needle placement, and proper administration techniques1
- Healthcare professionals administering KYBELLA® must understand the relevant submental anatomy and associated neuromuscular structures in the area involved, as well as any alterations to the anatomy due to prior surgical or aesthetic procedures1
Please click here for Important Safety Information.
INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
KYBELLA® is contraindicated in the presence of infection at the injection sites.
WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
Injection Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.
Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.
Injection Site Ulceration, Necrosis, and Infection
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration, necrosis, and infection have been reported with administration of KYBELLA®. Some cases of injection site infection have included cellulitis and abscess requiring antibiotic treatment and incision and drainage. Do not administer KYBELLA® into affected area until complete resolution.
ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see KYBELLA® full Prescribing Information.
References: 1. KYBELLA® Prescribing Information, March 2023. 2. Data on file, Allergan, September 29, 2015; Composite 1- and 2-grade responders.